Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 and up to 3.9 years treatment: an updated integrated analysis of 8 clinical trials
book_2
Source:
EADV Congress 2022 - Oral session
calendar_today
Published on Medfyle:
September 2022
import_contacts
4
min
In this medfyle
An integrated safety analysis across eight clinical trials in atopic dermatitis shows safety consistent with the known profile over 4 years of exposure.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a highlights summary of an oral session given at the EADV 2022 - 31st Congress and presented by:
Dr. Antonio Torrelo
Hospital Nino Jesus
Madrid, Spain
The content is produced by Infomedica, the official reporting partner of EADV 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
